Grace Capital’s Viking Therapeutics VKTX Stock Holding History

Grace Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-800	Closed	-$4K	–	274
2020 Q3	$4K	Hold	800	–	–	﹤0.01%	239
2020 Q2	$6K	Buy	+800	New	+$5.31K	0.01%	212

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Grace Capital's VKTX Position: Q4 2020 in Review

Grace Capital sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 800 shares — an estimated $4K sold.

Grace Capital first reported a position in VKTX in Q2 2020 and held it in 2 quarters. The position peaked at $6K in Q2 2020. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

Grace Capital reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
Grace Capital sold 800 Viking Therapeutics shares in Q4 2020, an estimated $4K.
Grace Capital first reported a position in Viking Therapeutics in Q2 2020 and held it in 2 quarters.
Grace Capital's Viking Therapeutics position peaked at $6K in Q2 2020.
143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Grace Capital's 13F filing for Q4 2020, filed 10 Feb 2021.